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A panel of monoclonal antibodies (mAbs) specific for the nucleocapsid (N) protein or the glycoprotein Gc of
Schmallenberg virus (SBV), a novel member of the Simbu serogroup (genus Orthobunyavirus, family Bunyaviridae),
was produced and used to analyze antigenic differences among members of this serogroup. Reactivity with various
SBV-isolates and other Simbu serogroup viruses was assessed by an indirect immunofluorescence test and by
immunoblotting. The Gc-specific mAbs detected different SBV isolates as well as two closely related members of
the Simbu serogroup. In addition, one mAb showed a highly specific reactivity with the homologous SBV strain
only. Based on their differing reactivity with different SBV-strains, these antibodies represent a valuable novel
tool to rapidly determine the phenotype of new SBV isolates. In contrast, the N-specific mAbs showed a broad
reactivity spectrum and detected not only all the tested SBV-isolates, but also several other viruses of the Simbu
serogroup. One out of these mAbs even recognized all of the tested Simbu serogroup viruses in the indirect
immunofluorescence assay. In order to further characterize the N-specific antibodies, PepScan analysis was performed
and a specific epitope could be identified. In summary, the newly generated mAbs showed differing pan-Simbu virus-,
pan-SBV- as well as SBV-isolate-specific reactivity patterns. Thus, they represent valuable tools for the development of
novel antigen and antibody detection systems either specific for SBV or, in a broader approach, for the pan-Simbu serogroup
diagnostics.Introduction
In late 2011, a hitherto unknown teratogenic orthobunya-
virus was discovered in Central Europe and named
Schmallenberg virus (SBV) [1]. It causes severe congeni-
tal malformation, stillbirth or premature birth, when preg-
nant ruminants are infected during a critical period of
gestation. SBV is a member of the genus Orthobunyavirus
within the family Bunyaviridae [1]. Orthobunyaviruses are
divided into 18 serogoups and among these SBV belongs
to the Simbu serogroup [2,3]. The closest relatives of SBV
are Sathuperi virus (SATV) and Douglas virus (DOUV)* Correspondence: martin.beer@fli.bund.de
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unless otherwise stated.[2]. However, the Simbu serogroup also includes Akabane
virus (AKAV) and Aino virus (AINOV), as well as
Oropouche virus (OROV), which is the only member
of the serogroup capable to infect humans.
Like in typical bunyaviruses, the SBV genome consists
of three single-stranded RNA segments which encode
six proteins. According to their size they are named
large (L), medium (M) and small (S). The nucleocapsid
(N) protein and a small non-structural protein (NSs) are
encoded in overlapping open reading frames by the S
segment, two glycoproteins (Gn and Gc), as well as a
non-structural protein (NSm) are encoded by the M seg-
ment, and the RNA-dependent RNA polymerase which
represents the central element of the orthobunyaviral rep-
lication complex [4] is encoded by the L segment [5,6].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gomerizes as a tetramer [7], and is not only essential for
viral genome encapsidation, but is also involved in viral
RNA‐transcription and replication [7,8]. Furthermore, it
is the most conserved protein among orthobunyaviruses,
and elicits a strong humoral immune response in in-
fected animals [9-11]. The glycoproteins Gn and Gc with
molecular masses of approximately 35 kDa and 110 kDa,
respectively, represent type I integral transmembrane
proteins which are further modified by N-linked glyco-
sylation [8]. They form spikes on the virus particle and
are essential for viral attachment and cell fusion. It has
been described before for certain bunyaviruses, that Gn
and Gc are targeted by neutralizing antibodies [5]. Simi-
lar roles are also assumed for the SBV Gn and Gc, but
remain to be confirmed. In contrast to the nucleocapsid
protein, the glycoproteins, especially Gc, show the most
variable sequences among the protein-coding genes of
SBV and related viruses [12-15].
Currently, molecular and serological detection systems
for SBV primarily base on the N-protein [16,17]. In the
present study, monoclonal antibodies (mAb) specific for
N as well as for Gc were prepared and characterized.
Special emphasis was set on the investigation of the suit-
ability of the mAbs for application in SBV diagnostics
and for the characterization of virus isolates.Materials and methods
Virus purification
SBV, strain BH80/11, was propagated in Vero cell mono-
layers and harvested when the cytopathic effect (CPE)
was maximal; supernatant fluid was clarified by centrifu-
gation at 4000 rpm for 30 min, added to 8% of PEG
6000 in 0.5 M NaCl, and then placed overnight at 4 °C
in agitation. The suspension was centrifuged at 5000 rpm
for 30 min and the pellet was resuspended in phosphate-
buffer saline solution, pH 7.4 (PBS) at a 20X concentration
compared to the initial volume. Following further clarifi-
cation by centrifugation (5000 rpm for 30 min), the
viral suspension was purified by ultracentrifugation at
35 000 rpm for 2 h (rotor TST41 Kontron) through a
25% (w/w) sucrose cushion and the pellet was resuspended
in PBS. The concentrated antigen was kept at −70 °C
until use.MAbs production
Two Balb/c mice were primed with intraperitoneal injec-
tions of 4 × 106 BHK-21 cells infected with SBV strain
BH80/11 (dilutions in PBS). After one month, mice were
boosted as follows: one using again the initial antigen
preparation, and the second one using partially purified
virus (500 μg of total protein containing approximately
50 μg of viral proteins).Three days after the boost, mice were humanely sacri-
ficed and hybridomas were generated by fusion of sple-
nocytes with NS0 myeloma cells following standard
procedures [18]. Briefly, at least 108 spleen cells were re-
covered from each mouse and fused with NS0 myeloma
cells at a 10:1 ratio using PEG 4000. Fused cells diluted
in Dulbecco’s modified Eagle medium, supplemented
with hypoxanthine/aminopterin/thymidine and 20% fetal
calf serum, were distributed over five microplates (200 μL
per well). Growing colonies were observed in all wells; in
order to select hybridomas secreting monoclonal anti-
bodies specific for SBV, the supernatants were screened by
indirect immunofluorescence (IIF) test using SBV-infected
Vero cells, grown into 96-well microplates and fixed by
80% acetone. Non-infected Vero cells served as negative
controls.
The positive hybridoma cells were cloned by limiting
dilution in order to obtain antibodies from one single
cell. The supernatant from exhausted cultures was then
used as source of mAb.
Indirect ELISA
ELISA was performed in 96-well Nunc Maxisorp ELISA
plates. The plates were coated over night at 4 °C using
50 μL/well of partially purified SBV-antigen at a saturat-
ing concentration (produced as described above) diluted
in ELISA coating buffer (0.05 M carbonate/bicarbonate
buffer, pH 9.6). Plates were washed three times with
250 μL of washing buffer (PBS containing 0.05% Tween
20) and subsequently incubated with 50 μL/well of un-
diluted hybridoma culture supernatants for 1 h at 37 °C.
After three washes, a peroxidase-conjugated goat anti-
mouse immunoglobulin antibody (produced in-house)
optimally diluted in PBS containing 0.05% Tween 20
and 1% yeast extract was incubated for 1 h at 37 °C.
After a final washing cycle, 50 μL/well of substrate solu-
tion (0.5 mg/mL orthophenylenediamine and 0.02%
H2O2 in 50 mM phosphate citrate buffer, pH 5) was
added. The colorimetric reaction was stopped after
10 min using 2 N sulfuric acid and the absorbance
values were read at 492 nm using an ELISA reader.
Virus-neutralization test (VNT)
Serial two-fold dilutions of each hybridoma supernatant
(duplicate wells) in 25 μL of serum-free culture medium
were incubated for 1 h at 37 °C with an equal volume of
cell culture supernatant containing 100 tissue culture in-
fectious dose 50 (TCID50) of SBV. Subsequently, 50 μL
of Vero cells at a dilution of 4 × 105 cells/mL in medium
containing 10% fetal calf serum were added to each well.
After incubation for 72–96 h at 37 °C with 5% CO2,
wells were scored for CPE and neutralizing titers were
expressed as the reciprocal of the final mAb dilution re-
quired to neutralize 100% of the inoculated cultures.
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The hybridoma supernatants were characterized by an
IIF-test using SBV-infected BHK-21 cells, clone BRS5
(L194, Collection of Cell Lines in veterinary Medicine
[CCLV]) as antigen matrix [17]. The BHK-21 cells were
infected with one of the following SBV strains: BH80/11
(isolated from bovine blood in 2011 on KC cells [L1062
CCLV]), BH619/12 (isolated from sheep serum in 2012 on
Vero cells [L0228 CCLV]), BH652/12 (isolated from bo-
vine blood in 2012 on BHK cells [L0164 CCLV]), D512/
12, D495/12-1, and D495/12-2 (all three isolated in 2012
and kindly provided by Andreas Moss, Lebensmittel- und
Veterinärinstitut Oldenburg, Germany). In addition, the
mAbs were tested against closely related Simbu serogroup
viruses, namely Simbu virus (SIMV), DOUV, SATV, Sabo
virus (SABOV), Shamonda virus (SHAV), AKAV, AINOV,
Peaton virus (PEAV), and OROV. All Simbu serogroup vi-
ruses were kindly provided by Peter Kirkland (Elizabeth
Macarthur Agricultural Institute, Australia) and Robert
Tesh (University of Texas Medical Branch, USA).
In addition, the mAbs were tested in DNA-transfected
BSR-T7/5 cells (L583 CCLV, [19]), transiently expressing
SBV-N, all M-segment encoded proteins (Gn, Gc, M)
and Gn or Gc separately. For the construction of the
expression plasmids pCITE_N, pCITE_M, pCITE_Gn
and pCITE_Gc, the open reading frame (ORF) of
SBV-N and SBV-M and the genomic regions encoding
Gn and Gc, respectively, were amplified by RT-PCR
from supernatants of SBV-infected BHK-21 cells.
RNA was isolated by using the QIAmp viral RNA
Mini Kit (Qiagen) and amplified with the QIAGEN
OneStep RT-PCR Kit (Qiagen). Primers used for S
were as follows: SBV_N_F (5’CCAATCTAGACCGAT
GTTGATACCGAATTGCTG 3’), SBV_N_R (3’ GAG
TGCGGCCGCTTTAGATGTTGATACCGAATTG 5’), for
M: SBV_Gn_F (5’ GAAAAACACGATGATAATACCATG
CTTCTCAACATTGTCTTG 3’), SBV_Gc_R (3’ GTGGT
GCTCGAGTGCGGCCGCTCACTT AAATTT ATTTTC
CATTT GG 5’), for Gn: SBV_Gn_F and SBV_Gn_R (3’ GT
GGTGCTCGAGTGCGGCCGCTT ACCTTGTTTTCG
GCAATGCT TTATAG 5’) and for Gc: SBV_Gc_F (5’ GA
AAAACA CGATGATAATACCATGGAAACTAG TATT
AACTGCAAAAACA 3’) and SBV_Gc_R. The RT-PCR
fragments were cloned into plasmid pCITE-2a (Novagen).
After XbaI/NcoI digestion, the PCR fragment of SBV-N
was ligated into the NcoI/XbaI digested plasmid resulting
in plasmid pCITE_N. Plasmid constructs pCITE_M, pCI-
TE_Gn and pCITE_Gc were generated by restriction-free
cloning [20]. For protein expression, plasmid-DNA was
transfected into BSR-T7/5 cells which stably express the
phage T7 RNA polymerase [19] using Lipofectamine 2000
(Invitrogen) according to manufacturer’s protocols. At
24 h post transfection, the transfected cells were used
for the investigation of the mAbs by IIF-staining.SDS–PAGE and Western blot analysis
The reactivity of the hybridoma supernatants with the
SBV-strains mentioned above as well as with SIMV,
DOUV, SATV, SABOV, SHAV, AKAV, AINOV, and
OROV was additionally analyzed by Western blot (WB).
The viruses were propagated on BHK-cells (L0164 CCLV)
and were deep frozen at −70 °C when a generalized cyto-
pathic effect became evident after 24 – 48 h post infection.
Uninfected BHK-cells were used as a negative control.
The proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under re-
ducing or non-reducing conditions and transferred onto a
nitrocellulose membrane using a Trans-Blot SD Semi-Dry
Transfer Cell device (Bio-Rad). The nitrocellulose mem-
branes were blocked for 1 h using 5% non-fat dry milk
diluted in PBS and subsequently incubated with the hy-
bridoma supernatants (diluted 1:20 in PBS) overnight at
4 °C followed by a horseradish peroxidase-conjugated
anti-mouse antibody (Dako, diluted 1:200 in PBS) for 1 h
at room temperature. Proteins were visualized using the
Super Signal West Pico Chemiluminescent substrat
(Thermo Scientific).
PepScan analysis of anti-N monoclonal antibodies
A library of biotinylated overlapping peptides covering
the entire N-protein sequence was synthesized (New
England Peptide, USA). Biotinylated peptides were 16
amino acids (aa) long with an overlap of 13 aa. Synthesis
was successful for all requested peptides except for pep-
tides number B10 and D08 which were excluded from
the analysis because they did not pass quality control
(please see Additional file 1 for sequence information).
Biotinylated peptides were coated on 96-well streptavi-
din plates (IDEXX International, USA) and the N-specific
mAbs were subsequently tested for binding activity on
each peptide. In addition, binding activity of full-length re-
combinant N-protein (rN) was assessed as a control on
the same plate. The rN-protein was cloned in pET28a and
expressed in E. coli BL21 cells (Novagen, UK). Water
soluble His-tagged protein was purified by affinity
chromatography on Ni2+-columns [21] and biotinylated
subsequently (EZ-Link® Sulfo-NHS-LC-Biotinylation Kit,
Thermo Scientific). The indirect ELISA was performed
as follows: Streptavidin plates were washed three times
with PBS containing 0.1% Tween-20. Peptides (5.0 to
7.5 mg/mL in DMSO) were diluted 1:400 in PBS
pH 7.2 and coated using 100 μL/well during 1 h at
room temperature. Plates were then washed three times
using washing buffer (PBS containing 0.1% Tween-20).
Subsequently, 100 μL of the diluted hybridoma superna-
tants were added to each well and incubated for 1 h at
room temperature. After three additional washing steps,
100 μL/well of goat anti-mouse peroxidase-conjugated
antibody (Bio-Rad) were added and incubated for 1 h at
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containing 0.1% Tween-20 and 10% goat serum. Finally,
the plates were washed three times with washing buffer
and subsequently 3,3′,5,5’-tetramethylbenzidine (TMB
substrate) was added to each well. The color development
was stopped after 10 min and optical densities (OD) were
measured at 450 nm using a spectrophotometer. When
two contiguous peptides were recognized, it was assumed
that the binding area was the common amino acid se-
quence of the two contiguous peptides.
The identified epitopes were highlighted in the three-




A panel of 47 hybridomas, generated by fusion processes
from two immunized mice, was found to produce mAbs
specifically reactive with homologous SBV in IIF and in-
direct ELISA tests.
In a preliminary characterization aimed at selection of
mAbs for further studies, the 47 MAbs showed two dif-
ferent immunofluorescence patterns (described in the
following paragraph), the majority reacted in western
blot with either a band of approximately 25 kDa or a
band of 110 kDa. The former did not show neutralizing
activity, while most of the latter did neutralize SBV in-
fectivity, suggesting a strong involvement of the target
protein in virus neutralization mechanisms.
After preliminary characterization and diversification,
a subset of 16 hybridomas was submitted to cloning pro-
cedures and the produced mAbs were used for the fol-
lowing more detailed investigations.
Evaluation of the 16 mAbs in VNT, IIF test and Western
blot analysis
In the IIF tests, six mAbs reacted with transiently
expressed SBV-N (pCITE_N transfected cells) and ten
with SBV-M (pCITE_M transfected cells) (Table 1).
When analyzed in WB (non-reducing conditions),
using the homologous strain BH80/11, four out of the
six SBV-N-reactive mAbs bound a protein of the ap-
proximate molecular weight of the N-protein (25 kDa,
Figure 1). The remaining two mAbs (3H9 and 3A11) did
not recognize any denatured SBV antigen in cell lysates
(Table 2). None of the six mAbs was reactive under re-
ducing conditions (data not shown). The 10 mAbs
which reacted with pCITE_M transfected cells de-
tected a Gc-specific band of about 110 kDa in WB
(Table 2 and Figure 1).
All mAbs showed a strong reactivity in BHK21-cells
infected with the homologous SBV strain BH80/11.
However, the individual mAbs showed different fluores-
cence staining patterns. By using the SBV-N-reactivemAbs a cytoplasmatic fluorescence and granular inclu-
sions could be observed (see Figure 2A for an example).
In contrast, a more diffuse, homogenous immunofluor-
escence around the nuclei of the infected cells was pro-
duced by SBV-M-reactive mAbs (Figure 2B).
Eventually, the target-specificity of the mAbs was de-
termined by combining the results of WB analysis and
IIF tests described above: 6 out of the 16 characterized
mAbs were specific for the N-protein, and 10 specifically
reacted with Gc. Investigation of the virus neutralizing
capability by VNT showed that none of the six anti-N
mAbs was able to neutralize virus infectivity, in contrast
to seven out of 10 anti-Gc mAbs, which demonstrated
neutralizing activity (Table 2).
Apart from the homologous strain BH80/11, five add-
itional SBV isolates were used to investigate the reactiv-
ity of the mAbs. The results of both, WB analysis and
IIF tests were in agreement for all isolates except for
mAb 5 F8 (Tables 1 and 2). In IIF, this antibody detected
4 out of 6 SBV isolates, whereas in WB, it reacted only
with the isolate BH80/11-4, which was used for the mAb
production.
The reactivity of the mAbs with nine related Simbu
viruses was subsequently also investigated. The N-specific
mAbs were able to detect DOUV, SATV, and SHAV in-
fected cells (see Figure 3 for an example) and four out
of six mAbs reacted also with SIMV, SABOV, and
AKAV infected cells in IIF tests. The mAb 1H4 even
showed a pan-Simbu reactivity as it detected all of the
tested Simbu serogroup viruses. Of the Gc-specific
mAbs, one detected SATV and four recognized SATV
as well as DOUV. However, the remaining 5 mAbs did
not recognize any of the tested Simbu viruses (Table 1).
In WB, all the SBV N-specific mAbs except 3H9 and
3A11 reacted with DOUV, SIMV, SATV, and SHAV,
three of them also detected SABOV and AKAV, and
mAb 1H4 showed reactivity with all tested Simbu vi-
ruses except AINOV. Among the Gc-specific mAbs,
one showed positive signals with DOUV and another
three were able to detect SATV (Table 2).
Epitope mapping and location on the three-dimensional
structure of anti-N monoclonal antibodies
The anti-N mAbs showed the broadest reactivity spectrum
against all the tested bunyaviruses, hence determining the
relevant epitopes could be helpful to explain the observed
patterns. For this purpose, a PepScan approach was ap-
plied, in which overlapping peptides that covered the
complete sequence of the N‐protein were synthesized and
tested with the respective mAbs in an ELISA.
The mAbs 4E12 and 1H4 showed a strong and repro-
ducible binding activity to some contiguous peptides
allowing the localization of the target epitope (Figures 4
and 5). MAb 4E12 bound strongly to the peptides A07,
Table 1 Characterization of anti-SBV mAbs by immunofluorescence test
MAbs indirect immunofluorescence test (IIFT) IIFT pCITE clones
Schmallenberg virus DOUV SIMV SATV SHAV SABOV AKAV AINOV PEAV OROV Schmallenberg virus
BH80/11-4 BH619/12-3 BH652/12 D512/12 D495/12-1 D495/12-2 S M Gc
4E12 + + + + + + + + + + + + - - - +
1H4 + + + + + + + + + + + + + + + +
3H3 + + + + + + + + + + + + - - - + -
3E3 + + + + + + + + + + + + - - - +
3H9 + + + + + + + - + + - - - - - + -
3A11 + + + + + + + - + + - - - - - +
2G10 + + + + + + - - - - - - - - - - + +
4D9 + + + + + + - - - - - - - - - - + +
2H11 + + + + + + + - + - - - - - - - + +
4E5 + + + + + + - - - - - - - - - - + +
5 F8 + + + + - - - - - - - - - - - + +
1C11 + + + + + + + - + - - - - - - + +
1 F4 + + + + + + - - + - - - - - - + +
4B6 + + + + + + - - - - - - - - - - + +
1C1 + + + + + + + - + - - - - - - - + +











Figure 1 Western blot analysis of mAbs 4E12 and 1F4. The anti-N mAb 4E12 is shown in lanes 1 to 7, and mAb 1F4 (anti-Gc) in lanes 7 to 13.
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MAb 1H4 bound strongly to the peptide A08 (OD 3.9)
and on a clearly lower level to A07 (OD 1.0). Since pep-
tides A07 (aa 19–34), A08 (aa 22–37) and A09 (aa 25–40)
are contiguous peptides within the N-protein of SBV
strain BH80/11 (Figure 5) it could be assumed that this aa
region represents the binding area of the mAbs 4E12 and
1H4 or is at least a part of it. However, for the remaining
four N-specific mAbs, no binding activity could be de-
tected in the peptide ELISA although all mAbs strongly
bound to the full length N-protein (Figure 4). Two of
these four mAbs showed also no reactivity in WB-
analyses, indicating a conformation-dependent nature of
their target epitopes.
The reactions of 3E3 and 4E12 with peptide F03 and
of 3H9 with peptides F01 and G01 could not be con-
firmed and are possibly due to conjugate artifacts.
The epitope formed by peptides A07, A08, and A09
corresponds to amino acid positions 19 to 40 of SBV
strain BH80/11 and could be localized at the external
face of the N-protein tetramer in the crystal structure of
SBV‐N [22] (Figure 6).
Discussion
The Simbu serogroup of the genus Orthobunyavirus
contains viruses of different medical and veterinary rele-
vance and members of this group have been isolated
worldwide [24]. OROV, the only virus in the serogroup
that can infect humans, was responsible for outbreaks of
acute febrile illness in South America [25,26]. AKAV, a
serious threat to the livestock industry, caused epizootics
of congenital defects in Asia, Australia, or in the Middle
East [27-30]. An AKAV-infection during a critical periodof gestation can lead to the birth of severely malformed
offspring, premature birth or stillbirth. Identical symp-
toms are induced by an infection of pregnant ruminants
with other members of the Simbu serogroup as e.g. AINOV
or SBV [30-34]. SBV, a novel orthobunyavirus and the first
European member of this serogroup, was discovered for the
first time in late 2011. Since then, the virus caused a large
epidemic in domestic and wild ruminants all over Europe
[35-37]. To enable early detection of an SBV-spread into
previously unaffected regions and to monitor emergence of
other Simbu serogroup viruses, sensitive and specific diag-
nostic test systems are required.
The N-protein represents the most abundant protein
in the virion as well as in virus-infected cells and is cur-
rently widely used for serological detection of SBV infec-
tions [16,17]. In addition, the N-protein encoding gene
provides a reliable target of SBV molecular diagnostics
tests. Furthermore, due to its high immunogenicity,
N-specific antibodies are detectable early after infec-
tion as well as in convalescent animals providing a re-
liable basis for serological diagnosis [38,39]. However,
due to the high sequence conservation of the N-gene,
antibody cross-reactivity occurs among members of the
same serogroup [17,40,41]. Accordingly, the N-specific
mAbs produced in the present study recognized several
viruses of the Simbu serogroup (Tables 1 and 2).
Nevertheless, only the mAb 1H4 allowed detection of
all the tested virus strains in the immunofluorescence
test. This antibody therefore represents a promising
candidate for the development of serological screening
tests which cover the entire Simbu serogroup. The
mAb could e.g. be applied in a blocking or competing
ELISA format.
Table 2 Characterization of anti-SBV mAbs by ELISA, neutralization test, and western blot
MAbs ELISA VNT Western blot (kDa)
Schmallenberg virus DOUV SIMV SATV SHAV SABOV AKAV AINOV OROV
BH80/11-4 BH619/12-3 BH652/12 D512/12 D495/12-1 D495/12-2 Specifity
4E12 + <1/2 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 - - nucleocapsid protein
1H4 + <1/2 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 - ~25 nucleocapsid protein
3H3 + <1/2 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 - - nucleocapsid protein
3E3 + <1/2 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 ~25 - - - - nucleocapsid protein
3H9 + <1/2 - - - - - - - - - - nucleocapsid protein
3A11 + <1/2 - - - - - - - - - - nucleocapsid protein
2G10 + <1/2 ~110 ~110 ~110 ~110 ~110 ~110 glycoprotein Gc
4D9 + pos ~110 ~110 ~110 ~110 ~110 ~110 glycoprotein Gc
2H11 + <1/2 ~110 ~110 ~110 ~110 ~110 ~110 ~110 - - - - glycoprotein Gc
4E5 + pos ~110 ~110 ~110 ~110 ~110 ~110 glycoprotein Gc
5 F8 + 1/8 ~110 - - - - - glycoprotein Gc
1C11 + 1/16 ~110 ~110 ~110 ~110 ~110 ~110 - - ~110 - - glycoprotein Gc
1 F4 + 1/4 ~110 ~110 ~110 ~110 ~110 ~110 - - - - - glycoprotein Gc
4B6 + 1/8 ~110 ~110 ~110 ~110 ~110 ~110 glycoprotein Gc
1C1 + 1/16 ~110 ~110 ~110 ~110 ~110 ~110 - ~110 - - glycoprotein Gc











Figure 2 Indirect immunofluorescence test. MAbs 4E12 (anti-N, A) and 1F4 (anti-Gc, B) were analyzed in an indirect immunofluorescence test
using BHK-21 cells infected with SBV strain BH80/11 as antigen matrix.
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4E12 could be localized to amino acid positions 19 to 40
of the SBV BH80/11-N-protein. These results are not in
agreement with a previously with another mAb identi-
fied antigenic epitope located between aa 51 to 76 [41].
However, the respective experiments have been per-
formed using a bacterially expressed full-length recom-
binant SBV-N-protein, whereas a peptide library was
applied in the present study, which might explain the di-
verging results. Using 3D modelling, the epitope recog-
nized by mAbs 1H4 and 4E12 could be located to the
external surface of the tetramer formed by the N‐protein
in complex with the RNA molecule, rendering this domain
accessible to the humoral immune system. However, eventhough these two mAbs bound to the same epitope in the
PepScan analysis, they showed differences in their reactiv-
ity with Simbu serogroup viruses in IIF and WB. It can
therefore be assumed that mAbs 1H4 and 4E12 bind to dif-
ferent key amino acid residues within overlapping linear
epitopes.
For several of the mAbs used in this study a specific
epitope could not be identified, indicating that the re-
spective antibodies bind to discontinuous epitopes [42].
In such cases, the antibodies are not directed against a
linear stretch of aa, but recognize a set of amino acid
residues in the antigen that are brought together only by
the folding of the molecule [42]. Since with the applied
PepScan technology only linear epitopes can be mapped,
Figure 3 Western blot analysis of mAbs 4E12 with Simbu
serogroup viruses. Mock-infected BHK-21 cells were used as
negative control.
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epitopes. This might explain the failure to define epi-
topes for each of the antibodies.
Virus neutralization activity was observed for none of
the generated anti-N mAbs, which is in agreement with
previous studies. Although N represents the immunodo-
minant protein in several members of the Bunyaviridae
family, it has been shown before, that anti-N antibodies
usually do not have neutralizing activity. In contrast, al-
most all neutralizing antibodies are directed against the
glycoproteins [9,43-45]. This is in accordance with the
results of the present study: 7 out of 10 mAbs specificFigure 4 PepScan analysis of the anti-N antibodies. Binding of mAbs 3
(filled triangle), 3H3 clone 2 (open square) 3H9 clone 4 (open triangle), and
(Np) peptides.for M-segment encoded proteins were positive in the
VNT. Furthermore, all the isolated glycoprotein-specific
antibodies were directed against Gc, suggesting that the
virus particle‐associated Gc is more immunogenic than
Gn. It has already been shown before in immunization
experiments, e.g. using the bunyavirus LaCrosse virus,
that the Gc-protein can be the main target of the
humoral immune response [9,46].
In contrast to the conserved S-segment, the M-segment
is variable between different SBV strains and between dif-
ferent virus species of the Simbu serogroup. A region of
especially high sequence variability was recently described
within the gene encoding Gc [13,14]. Consequently, five
out of the 10 Gc-specific mAbs exclusively detected SBV
isolates in the present study. The remaining five mAbs
additionally recognized DOUV and SATV, which are the
most closely related viruses to SBV based on M-segment
sequences [2]. However, cross-reactivity against other
Simbu serogroup viruses was not observed.
Interestingly, two of the mAbs which detected SBV as
well as DOUV and SATV (mAbs 1C1 and 1C11) are
possibly directed against the same epitope within the
Gc-glycoprotein. This was recently suggested based on
their identical reactivity profile with an escape-mutant
SBV (resistant to neutralization) which was generated by
mAb 1C11 (Brocchi and Cordioli, personal communica-
tion). In addition, the mAb 1C11 (or alternatively 1C1)
has already been successfully employed as competitor-
conjugated mAb in a competitive ELISA which allows
antibody detection in different species [47].
The mAb 2H11 did not bind as strong as the other Gc-
mAbs to Gc-protein expressed in transfected cells, even
though it recognized a product of the approximate molecu-
lar size of the mature Gc in western blot and reacted with
virus-infected cells in the IIF test. Maybe, this antibody rec-
ognizes the SBV-Gc better in a conformation which reliesE3 clone 10 (filled diamond), 4E12 clone 9 (filled square), 1H4 clone 7
3A11 clone 2 (filled circle) to full length N-protein (rNP) and to N-protein
Figure 5 Sequence alignment of N-protein of Simbu serogroup viruses. Amino acids that match those of SBV are indicated by dots. The linear
epitopes identified by using pepscanning are highlighted, a strong ELISA reaction is represented in dark grey (mAb 4E12) or dark blue (mAb 1H4),
whereas a weaker reaction is indicated in light grey (4E12) or light blue (1H4).
Figure 6 Location of the antigenic site of mAb 4E12 in the three-dimensional structure of SBV-N. The structure of SBV-N was obtained
from [22]. This figure was prepared using the PyMOL program [23].
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either reacts with the Gn‐Gc complex and/or with the Gc
alone once it is chaperoned by Gn. This hypothesis is sup-
ported by previous studies in Bunyamwera virus which
demonstrated the importance of Gn in the transport of Gc
to the Golgi and in Gc-Gn-heterodimerization [48,49].
Another intriguing finding of the present study was the
highly specific binding pattern of the Gc-specific mAb 5F8
which reacted almost exclusively with the homologous SBV
strain BH80/11. Similar observations have previously been
described for AKAV- and AINOV-specific mAbs [50,51].
However, the respective virus strains were isolated during a
period of more than 30 years (AKAV from 1959 to 1990,
and AINOV between 1964 and 1995) on two different con-
tinents, which explains the observed antigenic differences.
In contrast, the SBV strains used in the present study were
collected only during 2011 or 2012 and in a spatially limited
area. Nevertheless, different mAb-reactivity patterns were
obtained for these isolates. Thus, the mAbs investigated in
this study provide a valuable tool to rapidly determine the
phenotype of SBV isolates and to characterize newly emer-
ging virus strains. Furthermore, they represent attractive
options for the development of novel immunodiagnostic
assays which might allow differentiation of SBV and other
Simbu serogroup viruses.
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